In this study, we evaluated the potential of pretreatment cfDNA/ctDNA profiling as a biomarker to predict the efficacy and/or prognosis of combined anti-PD-L1 and anti-VEGF immunotherapy in u-HCC patients. This evidence concerns the gene VEGFA and hepatocellular carcinoma.